Full Generic Medicine Info
Dosage/Direction for Use

Allergic conditions
Adult: As conventional tab: 4 mg 4-6 hourly. Max: 24 mg daily. As extended-release tab: 12 mg 12 hourly. Max: 24 mg daily.
Child: 1-<2 years
1 mg bid; 2-5 years 1 mg 4-6 hourly. Max: 6 mg daily; 6-<12 years 2 mg 4-6 hourly. Max: 12 mg daily; ≥12 years Same as adult dose. Dosage recommendations may vary among countries or individual products. Refer to specific product guidelines.
Elderly: Dose reduction may be needed. Max: 12 mg daily.


Allergic conditions
Adult: 10-20 mg via IM, SC or slow IV inj over 1 minute. Max: 40 mg daily.
Child: 1 month to <1 year
0.25 mg/kg; 1-5 years 0.2 mg/kg or 2.5-5 mg; 6-12 years
0.2 mg/kg or 5-10 mg; >12 years
0.2 mg/kg or 10-20 mg.
Incompatibility: Incompatible with Ca chloride, kanamycin sulfate, noradrenaline acid tartrate, pentobarbital Na, and meglumine adipiodone.
May be taken with or without food.
Narrow-angle glaucoma, symptomatic prostate hypertrophy, acute asthma attacks, stenosing peptic ulcer, bladder neck or pyloroduodenal obstruction. Concomitant or within 14 days of MAOI use.
Special Precautions
Patient with CV disease (e.g. ischaemic heart disease, hypertension), increased intraocular pressure, thyroid dysfunction, asthma or other chronic breathing disorders (e.g. bronchitis), epilepsy, prostatic hyperplasia, genitourinary obstruction. Hepatic or renal impairment. Children and elderly. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness, dizziness, blurred vision and psychomotor impairment, if affected, do not drive or operate machinery.
Adverse Reactions
Significant: Sedation; excitation (in young children). Eye disorders: Blurred vision. Gastrointestinal disorders: Dry mouth, nausea, vomiting, diarrhoea, epigastric pain. General disorders and administration site conditions: Fatigue, lassitude. Metabolism and nutrition disorders: Anorexia, increased appetite. Nervous system disorders: Somnolence, disturbance in attention, abnormal coordination, dizziness, headache.
Symptoms: Sedation, paradoxical excitation of the CNS, toxic psychosis, apnoea, convulsions, anticholinergic effects, dystonic reactions, CV collapse (e.g. arrhythmias). Management: Symptomatic and supportive treatment. Gastric lavage or induced emesis using syrup of ipecacuanha may be considered. Activated charcoal can be given if overdosage is by the oral route, provided there are no contraindications for use and the overdose is recent (within 1 hour of ingestion). CNS convulsions may be treated with IV diazepam. Hypotension and arrhythmias should be treated vigorously. For severe cases, haemoperfusion may be used.
Drug Interactions
Enhanced sedative effect with other CNS depressants (e.g. barbiturates, hypnotics, opioid analgesics, sedatives, antipsychotics. Inhibits phenytoin metabolism which may lead to phenytoin toxicity.
Potentially Fatal: Increased anticholinergic effects with MAOIs.
Food Interaction
Enhanced CNS depression with alcohol.
Lab Interference
May suppress the wheal and flare reactions to skin test antigens.
Chlorphenamine, an alkylamine derivative, is a sedating antihistamine that competitively and reversibly inhibits histamine H1- receptor in the gastrointestinal and respiratory tract and blood vessels. This prevents the release of histamine, prostaglandins and leukotrienes, and also prevents the migration of inflammatory mediators. Synonym: chlorpheniramine.
Onset: Within 30 minutes.
Duration: 4-6 hours.
Absorption: Readily absorbed from the gastrointestinal tract. Bioavailability: 25-50%. Time to peak plasma concentration: 2.5-6 hours.
Distribution: Widely distributed in the body, including the CNS. Enters breast milk. Volume of distribution: 6-12 L/kg. Plasma protein binding: Approx 70%.
Metabolism: Extensively metabolised in the liver by CYP enzymes, including CYP2D6 to active and inactive metabolites, including desmethyl- and didesmethylchlorphenamine; undergoes extensive first-pass metabolism.
Excretion: Via urine (22% as unchanged drug); faeces (trace amounts). Elimination half-life: 2-43 hours.
Oral: Store between 20-25°C. Protect from light. Parenteral: Store below 25°C. Protect from light.
CIMS Class
Antihistamines & Antiallergics
ATC Classification
R06AB04 - chlorphenamine ; Belongs to the class of substituted alkylamines used as systemic antihistamines.
Disclaimer: This information is independently developed by CIMS based on chlorphenamine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in